Darunavir: an effective protease inhibitor for HIV-infected patients. - Wikidata - wikimedia - TriplyDB

Darunavir: an effective protease inhibitor for HIV-infected patients.

Darunavir: an effective protease inhibitor for HIV-infected patients.

http://www.wikidata.org/entity/Q37892551

about

Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.Long-chain triglycerides-based self-nanoemulsifying oily formulations (SNEOFs) of darunavir with improved lymphatic targeting potential.

P2860

Q30857727-B40C6AC4-3DB6-47DA-8A96-8964D3D86A0C Q36900555-DF577478-FA21-4FDC-B7EE-34DF2511644E Q39097668-FA52BF4C-BE6F-46B4-9D68-EBCB5FC6385C Q40084144-749C696E-1107-4079-AB50-1EDB910A0AFC

P2860

Darunavir: an effective protease inhibitor for HIV-infected patients.

http://www.wikidata.org/entity/Q37892551

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Darunavir: an effective protease inhibitor for HIV-infected patients.

@en

Darunavir: an effective protease inhibitor for HIV-infected patients.

@nl

type

label

Darunavir: an effective protease inhibitor for HIV-infected patients.

@en

Darunavir: an effective protease inhibitor for HIV-infected patients.

@nl

prefLabel

Darunavir: an effective protease inhibitor for HIV-infected patients.

@en

Darunavir: an effective protease inhibitor for HIV-infected patients.

@nl

P1433

Q37892551-3959254F-0FC6-4EA4-A61E-ABCFDA6416FA

P1476

Q37892551-7D748BCC-4570-4018-99B2-362D70AA5600

P2093

Q37892551-29DBA5F8-1FFA-43CC-804B-4B8F215491FF

Q37892551-C78FE447-615A-4BB5-AF1C-2AFE4395A507

P2860

Q37892551-09E6653D-AEEE-42F9-ABA5-2BCAC27B3BD7

Q37892551-237761A4-95BC-4129-B7B2-6CA261ACC343

Q37892551-2ECDB170-CD7B-4829-817C-2A90C956896C

Q37892551-3D50926F-F6F7-444E-9E33-6B0C8B52C915

Q37892551-3E3D9AD9-E7AA-451E-8E37-98C82EA05046

Q37892551-3F2DA46B-2D4F-4716-BE76-A7F38FDFECD3

Q37892551-42E9CF55-7F5D-44C7-BA0A-B9A6AEA80C39

Q37892551-48F1B73E-C91C-44DA-8677-1AAC6F194200

Q37892551-4C020D9F-21EF-4A21-9324-80382EDB46D8

Q37892551-4EB81F16-DB0B-4004-BB71-486029FC1A0B

P304

Q37892551-ED096C63-AE27-4AAC-818E-E6222939078A

P31

Q37892551-26D3769A-59AA-4A22-A284-6AA882A7C284

P356

Q37892551-3C556892-5289-4D8D-9C79-F09F6D7EB9C9

P433

Q37892551-0ED2FD4C-97BC-4FFE-B68C-F69EA8018FDD

P478

Q37892551-C5B0C45D-7F15-4243-9375-D69BA13708EB

P577

Q37892551-07C714B9-6FEA-4A53-AA19-F2521CA697A0

P698

Q37892551-94111A70-0B08-464C-A0D6-98F34BCBF03B

P356

P1433

Expert Review of Anti-infective Therapy

P1476

Darunavir: an effective protease inhibitor for HIV-infected patients.

@en

P2093

Bao-Chau Phung

http://www.w3.org/2001/XMLSchema#string

Patrick Yeni

http://www.w3.org/2001/XMLSchema#string

P2860

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.

Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

P304

631-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERI.11.48

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21692667

http://www.w3.org/2001/XMLSchema#string